Lunai Bioworks Expands Naked Short Selling Litigation Against Brokers

The company, a Sacramento-based developer of AI-driven precision medicine, asserts that these financial entities engaged in illegal naked short selling practices that harmed its market standing. By targeting specific broker-dealers under Rule 10b-5, Lunai is attempting to hold market intermediaries directly accountable for the volatility and downward pressure on its Nasdaq-listed shares. The case, registered under Civil Action No. 26-549-CFC, moves beyond the initial scope of the litigation to implicate those Lunai claims facilitated the alleged manipulation.

Lunai Bioworks currently utilizes its proprietary Augusta platform to advance research in neurology and biodefense, seeking to translate complex biomedical data into therapeutic insights. While the company pursues these claims, it maintains that the allegations remain unproven in court. The named defendants are presumed to have meritorious defenses, and the ultimate success of the litigation hinges on the discovery process and the court’s reception of the company’s legal theories regarding securities fraud.